Skip to main content

Priapism Management — Pharmacologic Agents

Intracavernosal phenylephrine is the first-line pharmacologic treatment for acute ischemic priapism, recommended by both the AUA/SMSNA 2022 and EAU guidelines.[1][2][3] For prevention of recurrent ("stuttering") priapism, the AUA explicitly states that optimal strategies are unknown (Conditional Recommendation; Grade C), though multiple agents — regimented PDE5 inhibitors, ketoconazole + prednisone, etilefrine, pseudoephedrine, and hormonal modulators — have evidence ranging from small retrospective series to a single underpowered RCT.[1]

For adjacent topics, see Intracavernosal injection agents, PDE5 inhibitors, and Androgen adjuncts.

Intracavernosal phenylephrine — acute ischemic priapism​

Why phenylephrine​

Selective α₁-adrenergic agonist — contraction of cavernosal smooth muscle, constriction of cavernosal arterioles, compression of subtunical venules, and promotion of venous outflow. Preferred over epinephrine or norepinephrine because it has minimal β-adrenergic activity, producing less tachycardia and fewer arrhythmias.[2]

Guideline status​

  • AUA/SMSNA 2022 — intracavernosal phenylephrine is the initial treatment for prolonged erection ≥4 h after ICI (Expert Opinion) and for acute ischemic priapism (Moderate Recommendation; Grade C)[1]
  • EAU — penile aspiration + intracavernosal sympathomimetic injection is the initial management of ischemic priapism[3]

Dilution and dosing protocol​

Preparation (standard):[2][4]

  1. Add 1 mL phenylephrine (10 mg/mL) to 9 mL NS → 1 mg/mL (1,000 µg/mL) working stock
  2. For patients with CV risk: take 1 mL of the stock and add to 9 mL NS → 100 µg/mL dilute solution

Dosing:

PopulationDoseInterval
Adult without CV risk100–500 µg (0.1–0.5 mL of 1 mg/mL)q3–5 min
Adult with CVD or hypertension100–200 µg (use 100 µg/mL dilution)q3–5 min
Children / adolescents1–5 µg/kgq3–5 min
Traditional ceiling~1,000 µg (1 mg) per hour—

Real-world data support safe cumulative use beyond 1 mg/hour in monitored settings — no clear dose-response relationship has been established.[5][4]

Technique​

  1. 19-gauge butterfly needle or angiocatheter into the lateral corpus cavernosum at 3 or 9 o'clock (avoid dorsal NVB and urethra)
  2. Aspirate dark deoxygenated blood — confirms ischemic priapism; send for blood gas if diagnostic (pO₂ <30 mmHg, pCO₂ >60 mmHg, pH <7.25)
  3. Irrigate with NS until bright-red blood returns
  4. Inject phenylephrine 100–500 µg in 1 mL saline; compress the corpora for 1 min after injection
  5. Re-dose q3–5 min; continuous BP and HR monitoring[2][6]

Efficacy​

StudynResolutionKey finding
Scarberry 202212363.9% PE aloneResolution tracked duration (8.8 vs 57.3 h; p < 0.001); no dose-response; 17.1% hemodynamic-risk; 4.1% stopped for hemodynamic change[5]
Sidhu 201874 encounters91% (53/58 receiving PE)Median 1,000 µg; no significant BP/HR change; no AEs[4]
Ridyard 201658 patients / 136 encounters86% non-surgical; 94% overall100% success if presenting <12 h; no complications from high-dose PE[7]
Muruve 1996989% (8/9)0.5 mg per injection; 1–6 injections; no aspiration/irrigation performed[8]
EAU systematic review 202441+ studies0–100% ICI alone; 70–100% ICI + aspiration ± irrigationCombined ICI + aspiration/irrigation most effective[3]

The dominant determinant of success is duration of priapism before treatment — resolution rates fall sharply after 24–36 h, and follow-up ED rates reach 30–70% after >24 h of untreated priapism.[3][5]

Safety​

  • Hypertension — clinically significant; monitor BP q5–15 min[5][4]
  • Reflex bradycardia — secondary to BP rise
  • Headache, dizziness; theoretical arrhythmia risk (minimized by α₁-selectivity)
  • Sidhu 2018 observed small but statistically significant decreases in HR (−4.2 BPM), SBP (−1.8 mmHg), and DBP (−5.4 mmHg); no AEs[4]
  • Scarberry 2022 — 17.1% at hemodynamic risk; 4.1% had phenylephrine discontinued for hemodynamic change; periprocedural safety assessment is under-reported and should be standardized[5]

Other intracavernosal sympathomimetics​

AgentMechanismDoseRole / concern
EpinephrineNon-selective α + β agonist10–20 µg intracavernosal (1:100,000)Historically used; largely replaced by phenylephrine due to tachycardia, palpitations, arrhythmias[2]
Norepinephrineα₁ + α₂ + some β₁10–20 µg intracavernosalUsed in some European centers; greater systemic CV effects than phenylephrine[2]
Etilefrine (intracavernosal)Mixed α + β (α₁ predominant)Self-administered for acute stuttering episodes >1 hVirag 1996 SCD series: dual oral prevention + ICI rescue protocol; not available in the US[9]

Expert consensus: intracavernosal phenylephrine is superior due to demonstrated efficacy and limited systemic side effects.[2]

Methylene blue — pharmacologically induced priapism​

Mechanism. Guanylate cyclase inhibitor — blocks the NO-cGMP pathway, interrupting endothelium-mediated cavernosal relaxation.[10][11]

Protocol (Martínez Portillo):[10]

  1. Aspirate blood
  2. Inject 5 mL methylene blue 1% (50 mg) intracavernosally
  3. Leave in place 5 min
  4. Aspirate the methylene blue
  5. Compress the penis 5 min

Efficacy:

  • Martínez Portillo series (n = 12) — 100% resolution of pharmacologically-induced priapism (10/10 CCIT-induced); two non-pharmacologic cases did not respond[10]
  • deHoll 1998 (n = 11) — 67% immediate detumescence; 100% in pharmacologic / trazodone-induced cases[12]

AEs: transient blue discoloration; injection-site burning; theoretical methemoglobinemia at high doses; potential serotonin-syndrome interaction with serotonergic drugs.

Status: second-line / rescue for pharmacologically induced priapism; not in current AUA or EAU algorithms but described in the literature as a reasonable option when phenylephrine fails or is contraindicated.[10][13]

Oral sympathomimetics — prolonged erection <4 h​

For prolonged erections <4 h post-ICI, oral agents may be tried before escalating to intracavernosal phenylephrine.[1]

Lowe & Jarow 1993 RCT (n = 75, PGE1-induced prolonged erections):[14]

AgentDoseDetumescencep vs placebo (12%)
Terbutaline5 mg PO36%Significant
Pseudoephedrine60 mg PO28%Not significant
  • Terbutaline — β₂-agonist; tremor, tachycardia, palpitations; only oral agent with significant efficacy vs placebo in a RCT[14]
  • Pseudoephedrine — indirect sympathomimetic; AUA notes CV AEs are common; sparse evidence for prevention[1]
  • Midodrine — α₁-agonist prodrug; single dose not superior to placebo; case series (n = 14) showed 100% detumescence at 15–30 mg but with BP/HR elevation[1]

Prevention of recurrent (stuttering) priapism​

AUA/SMSNA 2022 framing: "Clinicians should inform patients with recurrent ischemic priapism that optimal strategies to prevent subsequent episodes are unknown" (Conditional Recommendation; Grade C).[1]

1. Regimented daily PDE5 inhibitors — the counterintuitive first-line​

Mechanism (paradoxical). In SCD and idiopathic recurrent priapism, chronic hemolysis and oxidative stress reduce NO bioavailability → decreased cGMP → downregulation of PDE5 expression in cavernosal tissue. Without adequate PDE5, the feedback mechanism that terminates erections is impaired — chronic, low-dose PDE5i administration upregulates PDE5 expression and restores the regulatory loop.[15][16]

Dosing (literature):[17][18]

  • Sildenafil 25–50 mg daily — timed to morning or afternoon, not linked to sleep or sexual activity
  • Tadalafil 5 mg daily (used in Idris 2025 Phase 2 RCT)
  • The key principle is regimented daily dosing — not on-demand use

Evidence:

StudynDesignKey finding
Burnett 20067Retrospective case series6/7 (86%) resolution or alleviation; EF preserved[16]
Burnett 2014 RCT13Double-blind, placebo-controlledSildenafil 50 mg daily × 8 wk — no significant difference vs placebo in blinded phase; 62.5% met primary outcome in open-label phase; major episodes decreased 4-fold "on-treatment"[17]
Hou & Burnett 202124 evaluableRetrospectiveRegimented PDE5i — ED visits ↓ 4.4-fold (p < 0.001); 92% reported improvement; 9/24 complete resolution[18]
Cochrane 202013 (Burnett RCT)Systematic review"Sildenafil may make little or no difference" (low certainty) — based on the single small RCT[19]
Idris 2025 Phase 2 RCT64HU + tadalafil vs HU + placeboNo between-arm difference (IRR 0.8); both arms had 58–66% reduction from pre-randomization rates — supports HU's intrinsic effect[20]

AUA position: conflicting trial efficacy, but recent real-world data support regimented PDE5i as a reasonable first-line preventive strategy — Hou & Burnett 2021's 4.4-fold ED-visit reduction is the strongest contemporary signal.[1][18]

2. Ketoconazole + prednisone — highest reported success rate​

Mechanism. Ketoconazole inhibits adrenal and gonadal testosterone synthesis (CYP17A1) → suppresses sleep-related erections that seed priapism events. Prednisone replaces concurrently suppressed cortisol.[21][22]

Levine protocol (evolved):[22]

  • Initial: ketoconazole 200 mg TID + prednisone 5 mg daily × 2 weeks
  • Maintenance: ketoconazole 200 mg nightly × 6 months
  • Target testosterone ~200 ng/dL
  • Monitor monthly testosterone and LFTs; titrate

Evidence:

  • Hoeh & Levine 2014 (n = 17) — 94% complete resolution on treatment; mean ER visits 6.5 → 0; 78.6% had partial or complete resolution persisting after discontinuation (mean f/u 36.7 mo); IIEF-5 24.8 (preserved EF)[22]
  • Abern & Levine 2009 (n = 8) — similar results with testosterone-guided titration[21]

AUA position: "Ketoconazole with prednisone has the highest success rate, but should be used with caution considering its potential liver toxicity, thus warranting frequent assessment of liver function tests."[1]

AEs: hepatotoxicity (FDA boxed warning on ketoconazole), nausea / vomiting, adrenal insufficiency (mitigated by prednisone), hypogonadal symptoms.

3. Etilefrine (oral — prevention)​

  • α-agonist; cavernosal smooth-muscle contraction
  • Dose: 50–100 mg/day PO (typically 50 mg at bedtime)[23][9]
  • Okpala 2002 (n = 18 adult SCD) — 72% good clinical response; 1–48 mo follow-up; no hypertension or sexual dysfunction[23]
  • Virag 1996 (n = 6 SCD) — all protected against acute priapism on oral etilefrine; 4/6 controlled on oral alone; described the dual oral + ICI rescue protocol[9]
  • Cochrane 2020 — Olujohungbe 2011 4-arm RCT (etilefrine 50 mg vs ephedrine 15 / 30 mg vs placebo, n = 78, 6 mo) — very low certainty; uncertainty about efficacy[19]
  • Not available in the US — used in UK, Europe, Africa[1]

4. Other hormonal modulators​

The AUA cautions: "Hormonal regulators may impair fertility and sexual function" (Strong Recommendation; Grade B).[1]

AgentMechanismEvidenceLimitations
Cyproterone acetateAnti-androgen (progestational)High complete-response rates in case series; high withdrawal from AEsNot available in US; hypogonadal symptoms; impairs fertility[1]
GnRH agonists (leuprolide)Suppresses LH/FSH → chemical castrationCase reports / small series; effective but profound hypogonadismSevere hypogonadal symptoms; impairs fertility; bone loss[24]
Dutasteride5α-reductase inhibitor → reduces DHTListed by AUA as preventive option; very limited dataMinimal testosterone suppression; may impair fertility[1]
BicalutamideNon-steroidal anti-androgenCase reports onlyGynecomastia; hepatotoxicity risk

5. Baclofen​

GABA-B agonist — reduces sacral parasympathetic outflow. 10–20 mg TID titrated. Listed by AUA among preventive strategies for idiopathic recurrent ischemic priapism; evidence is case-report level. Sedation, dizziness, and withdrawal seizures if discontinued abruptly are the major cautions.[1][24]

6. Pseudoephedrine (oral — prevention)​

30–60 mg at bedtime. Listed by AUA; evidence is sparse case-series level. Cardiovascular AEs (hypertension, tachycardia, insomnia) are the main concern.[1]

7. Home self-injection of phenylephrine​

The AUA notes that home self-injection of phenylephrine on an as-needed basis is "reasonable" to abort episodes that have not yet reached the 4-h threshold. This is an acute rescue measure, not a preventive strategy. Requires careful patient education, technique training, and clear guidance on when to seek ED care.[1]

Sickle cell disease — disease-modifying therapy​

For SCD-related recurrent priapism, SCD-specific therapy is relevant:[1][20]

  • Hydroxyurea — reduces sickling, hemolysis, vaso-occlusive events; Idris 2025 Phase 2 RCT showed a 58% reduction in priapism events with hydroxyurea + placebo (pre-post analysis), suggesting HU itself drives the observed benefit
  • Chronic transfusion program — monthly exchange or simple transfusion to maintain HbS <30%
  • Acute exchange transfusion — the AUA explicitly states: do not delay intracavernosal phenylephrine and corporal aspiration to plan / perform acute exchange transfusion; no evidence it terminates episodes sooner than urologic intervention
  • Preoperative simple transfusion — if operative shunting is required, raise hemoglobin to 9–10 g/dL before general anesthesia

Treatment algorithm (synthesized)​

Acute ischemic priapism (≥4 h)​

  1. Corporal aspiration (19-g lateral) → blood gas
  2. NS irrigation until bright-red blood returns
  3. Intracavernosal phenylephrine 100–500 µg q3–5 min (~1 mg/h); monitor BP/HR
  4. If no response in 1 h → repeat aspiration / irrigation / injection cycle
  5. If refractory → distal shunt (Winter, Ebbehoj, Al-Ghorab) within 24–48 h
  6. If distal shunt fails → proximal shunt (Quackels, Sacher) or tunneling (Burnett snake maneuver)
  7. If >36–48 h or all shunts fail → penile prosthesis insertion[6][2]

Prolonged erection <4 h post-ICI​

  1. Conservative measures — ambulation, ice packs, micturition
  2. Oral terbutaline 5 mg or pseudoephedrine 60 mg[14]
  3. Intracavernosal phenylephrine if conservative measures fail or erection approaches 4 h[1]

Recurrent (stuttering) priapism prevention​

  1. First-line: regimented daily PDE5 inhibitor — sildenafil 25–50 mg or tadalafil 5 mg daily[18][1]
  2. Second-line (highest reported success but hepatotoxicity): ketoconazole 200 mg QHS + prednisone 5 mg daily × 6 mo[22]
  3. Alternatives: oral etilefrine 50 mg QHS (where available), pseudoephedrine, baclofen, dutasteride[1]
  4. Rescue: home self-injection of phenylephrine for episodes approaching 4 h[1]
  5. SCD-specific: hydroxyurea and/or chronic transfusion[1][20]
  6. Last resort: hormonal suppression (GnRH agonists, cyproterone) — effective but significant fertility and sexual-function impact[1]

Evidence Summary​

AgentSettingRouteEvidenceKey source
PhenylephrineAcute ischemic priapismIntracavernosalModerate (case series; AUA/EAU recommended)AUA/SMSNA 2022[1]; EAU 2024[3]; Scarberry 2022[5]
TerbutalineProlonged erection post-ICIOralLow (1 small RCT)Lowe & Jarow 1993[14]
PseudoephedrineProlonged erection / preventionOralVery lowLowe & Jarow 1993[14]; AUA 2022[1]
EtilefrinePrevention (SCD)Oral / ICIVery low (Cochrane); moderate (case series)Okpala 2002[23]; Virag 1996[9]
PDE5i (daily)Prevention (stuttering)OralLow (1 underpowered RCT); moderate (retrospective)Burnett 2014[17]; Hou & Burnett 2021[18]; AUA 2022[1]
Ketoconazole + prednisonePreventionOralLow (case series)Hoeh & Levine 2014[22]; Abern & Levine 2009[21]
Methylene blueAcute (pharmacologic)IntracavernosalVery lowMartínez Portillo 2001[10]
HydroxyureaPrevention (SCD)OralModerate (Phase 2 RCT)Idris 2025[20]

Clinical Positioning​

  • Intracavernosal phenylephrine is the first-line pharmacologic treatment for acute ischemic priapism. 100–500 µg q3–5 min with BP/HR monitoring; no clear dose-response above 1 mg/h in monitored settings.[1][5][4]
  • Time is the dominant prognostic variable. Resolution rates fall sharply after 24–36 h; ED rates climb to 30–70% at follow-up when priapism exceeds 24 h.[3][5]
  • Aspiration + irrigation + phenylephrine outperforms phenylephrine alone in the EAU systematic review — combine the maneuvers from the outset.[3]
  • For prolonged erections <4 h post-ICI, terbutaline 5 mg PO is the best-supported oral option (Lowe & Jarow RCT); pseudoephedrine is not significantly better than placebo.[14]
  • Methylene blue is a legitimate rescue for pharmacologically-induced priapism when phenylephrine fails — 100% resolution in the Martínez Portillo CCIT-induced series. Not in guideline algorithms but described in the literature.[10]
  • For recurrent ischemic priapism, regimented daily PDE5i (sildenafil 25–50 mg or tadalafil 5 mg daily) is the pragmatic first-line. The Burnett 2014 RCT did not reach significance, but Hou & Burnett 2021 real-world data show a 4.4-fold reduction in ED visits with 92% patient-reported improvement.[17][18]
  • Ketoconazole + prednisone has the highest reported success rate (94% on treatment, durable after discontinuation) but carries a hepatotoxicity boxed warning and requires LFT + testosterone monitoring. Reserve for PDE5i failures.[22]
  • Do not delay acute urologic intervention for SCD exchange transfusion — AUA is explicit on this.[1]
  • In SCD, hydroxyurea itself reduces priapism events (Idris 2025 58–66% reduction from baseline in both RCT arms) and should be part of the prevention strategy.[20]
  • Home self-injection of phenylephrine is an acute rescue, not a preventive strategy. Select, train, and counsel carefully; patients should still present if a self-injected rescue fails to resolve within the expected window.[1]
  • Hormonal suppression (GnRH agonists, cyproterone, anti-androgens) is a last resort — effective but significant fertility and sexual-function compromise; counsel explicitly per AUA Strong Recommendation.[1]

See Also​

References​

1. Bivalacqua TJ, Allen BK, Brock GB, et al. "The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline." J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

2. Graham BA, Wael A, Jack C, Rohan MA, Wayne HJG. "An overview of emergency pharmacotherapy for priapism." Expert Opin Pharmacother. 2022;23(12):1371–1380. doi:10.1080/14656566.2022.2099271

3. Capogrosso P, Dimitropolous K, Russo GI, et al. "Conservative and medical treatments of non-sickle-cell-disease-related ischemic priapism: a systematic review by the EAU Sexual and Reproductive Health Panel." Int J Impot Res. 2024;36(1):6–19. doi:10.1038/s41443-022-00592-2

4. Sidhu AS, Wayne GF, Kim BJ, et al. "The hemodynamic effects of intracavernosal phenylephrine for the treatment of ischemic priapism." J Sex Med. 2018;15(7):990–996. doi:10.1016/j.jsxm.2018.05.012

5. Scarberry K, Deebel NA, Dutta R, Matz E, Terlecki RP. "Safety and efficacy of phenylephrine administration for the treatment of ischemic priapism: an opportunity for quality improvement in periprocedural safety assessment." Urology. 2022;169:115–119. doi:10.1016/j.urology.2022.08.011

6. Pang KH, Alnajjar HM, Lal A, Muneer A. "An update on mechanisms and treatment options for priapism." Nat Rev Urol. 2025. doi:10.1038/s41585-025-01069-9

7. Ridyard DG, Phillips EA, Vincent W, Munarriz R. "Use of high-dose phenylephrine in the treatment of ischemic priapism: five-year experience at a single institution." J Sex Med. 2016;13(11):1704–1707. doi:10.1016/j.jsxm.2016.09.010

8. Muruve N, Hosking DH. "Intracorporeal phenylephrine in the treatment of priapism." J Urol. 1996;155(1):141–143.

9. Virag R, Bachir D, Lee K, Galacteros F. "Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine." Urology. 1996;47(5):777–781. doi:10.1016/s0090-4295(96)00027-1

10. Martínez Portillo F, Hoang-Boehm J, Weiss J, Alken P, Jünemann K. "Methylene blue as a successful treatment alternative for pharmacologically induced priapism." Eur Urol. 2001;39(1):20–23. doi:10.1159/000052407

11. Steers WD, Selby JB. "Use of methylene blue and selective embolization of the pudendal artery for high-flow priapism refractory to medical and surgical treatments." J Urol. 1991;146(5):1361–1363. doi:10.1016/s0022-5347(17)38095-3

12. deHoll JD, Shin PA, Angle JF, Steers WD. "Alternative approaches to the management of priapism." Int J Impot Res. 1998;10(1):11–14. doi:10.1038/sj.ijir.3900308

13. Martínez Portillo FJ, Jünemann KP. "New aspects in the treatment of priapism." Andrologia. 1999;31(Suppl 1):53–58. doi:10.1111/j.1439-0272.1999.tb01451.x

14. Lowe FC, Jarow JP. "Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections." Urology. 1993;42(1):51–53. doi:10.1016/0090-4295(93)90338-b

15. Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. "Nitric oxide resistance in priapism associated with sickle cell disease: mechanisms, therapeutic challenges, and future directions." J Pharmacol Exp Ther. 2024;390(2):203–212. doi:10.1124/jpet.123.001962

16. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. "Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism." J Sex Med. 2006;3(6):1077–1084. doi:10.1111/j.1743-6109.2006.00333.x

17. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. "Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease." Am J Med. 2014;127(7):664–668. doi:10.1016/j.amjmed.2014.03.019

18. Hou LT, Burnett AL. "Regimented phosphodiesterase type 5 inhibitor use reduces emergency department visits for recurrent ischemic priapism." J Urol. 2021;205(2):545–553. doi:10.1097/JU.0000000000001365

19. Chinegwundoh FI, Smith S, Anie KA. "Treatments for priapism in boys and men with sickle cell disease." Cochrane Database Syst Rev. 2020;4:CD004198. doi:10.1002/14651858.CD004198.pub4

20. Idris IM, Yusuf AA, Ismail II, et al. "A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil." Blood. 2025;145(26):3101–3112. doi:10.1182/blood.2024027898

21. Abern MR, Levine LA. "Ketoconazole and prednisone to prevent recurrent ischemic priapism." J Urol. 2009;182(4):1401–1406. doi:10.1016/j.juro.2009.06.040

22. Hoeh MP, Levine LA. "Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes." J Sex Med. 2014;11(1):197–204. doi:10.1111/jsm.12359

23. Okpala I, Westerdale N, Jegede T, Cheung B. "Etilefrine for the prevention of priapism in adult sickle cell disease." Br J Haematol. 2002;118(3):918–921. doi:10.1046/j.1365-2141.2002.03691.x

24. Migliorini F, Porcaro AB, Baldassarre R, Artibani W. "Idiopathic stuttering priapism treated with salbutamol orally: a case report." Andrologia. 2016;48(2):238–240. doi:10.1111/and.12438